BCL2 and glioma: In vivo, tumorigenic assays showed that HDAC2 downregulation and Bcl2 inhibited tumorigenic activity and enhanced apoptosis in glioma cells, while DNMT3B promoted tumorigenic activity and inhibited apoptosis in tissues.